Article
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.
Oncoimmunology - 1 Jan 2020
Saulite Ieva, Ignatova Desislava, Chang Yun-Tsan, Fassnacht Christina, Dimitriou Florentia, Varypataki Eleni, Anzengruber Florian, Nägeli Mirjam, Cozzio Antonio, Dummer Reinhard, Scarisbrick Julia, Pascolo Steve, Hoetzenecker Wolfram, Bobrowicz Malgorzata, Guenova Emmanuella
Abstract excerpt
Sézary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphoma (L-CTCL) that arises from malignant clonally derived skin-homing CD4+ T cells. Based on advancements in our understanding of the mechanisms underlying L-CTCL, boosting the suppressed immune response emerges as a promising strategy in SS management. Immune checkpoint inhibitory molecules have already demonstrated efficacy in a wide...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.